A new study shows that combining size-based and count-based analysis helps determine whether a copy number aberration originates in the mother, fetus, or both.
The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.
The company has also expanded its current Veracity NIPT to sex chromosomal aneuplodies and twin pregnancies, and plans to offer microdeletion testing next year.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
A re-analysis of non-invasive prenatal testing data from CARE found fewer false-positive cases caused by maternal copy number variants and other factors.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
